Ismo Retard (Isosorbide Mononitrate)

The drug releases nitric oxide after oral absorption. Nitric oxide activates guanylate cyclase in vascular smooth muscle, raising cyclic GMP levels. This cascade relaxes both arteries and veins, lowering preload and afterload, which decreases the heart’s workload and oxygen consumption.

The exact dose of Ismo Retard is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerance. Physicians typically start with a low dose and may adjust it gradually, but specific dosing regimens should not be inferred without a medical prescription.

Safety data for Isosorbide Mononitrate during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ismo Retard belongs to the organic nitrate class, offering once‑daily dosing and a longer half‑life compared with short‑acting nitrates like nitroglycerin. Unlike beta‑blockers or calcium‑channel blockers, its primary action is vasodilation, making it useful as a first‑line prophylactic agent or in combination therapy when other classes are insufficient.

Store Ismo Retard at ambient temperature below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral tablet formulation.

Ismo Retard is taken orally, usually as a whole tablet swallowed with a glass of water. It is generally prescribed for once‑daily administration, but the exact timing and frequency are set by the prescriber according to the patient’s therapeutic plan.

Serious adverse events include severe hypotension, syncope, myocardial infarction, life‑threatening arrhythmias, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, chest pain, or any signs of an allergic response.

Ismo Retard is contraindicated in patients with severe hypotension, recent myocardial infarction, concurrent use of other organic nitrates or PDE‑5 inhibitors, and those with known hypersensitivity to Isosorbide Mononitrate or any excipients in the tablet. Clinicians must evaluate each patient’s medical history before prescribing.